Conditions: Systemic Lupus Erythematosus
Keywords: SLE Belimumab Antibodies Systemic Lupus Erythematosus Lupus Autoimmune Diseases
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 738
Healthy volunteers: no

Brief summary:
This is a long-term continuation study to provide continuing treatment to subjects with SLE.

Detailed description:
This trial is a long-term continuation study to provide continuing treatment to subjects with System Lupus Erythematosus (SLE).

Arms:
arm 1: 1 mg/kg dose of belimumab given IV every 28 days. arm 2: 10 mg/kg dose of belimumab given IV every 28 days.

Interventions: intervention 1: belimumab
Intervention descriptions: intervention 1: Recombinant, fully human, monoclonal antibody

Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days.

Protocol document: